News & Updates

Show Multimedia Only

Chronic liver disease ups risk of post-ERCP complications

23 Feb 2026

Endoscopic retrograde cholangiopancreatography (ERCP), although deemed safe, is associated with the highest risk of complications when compared with other endoscopic procedures, reveals a study.

Chronic liver disease ups risk of post-ERCP complications

23 Feb 2026

Young at gut: How to modulate the microbiome for healthy ageing?

23 Feb 2026 by

At the Microbiome Summit 2026, experts shared insights into how the gut microbiome can be modulated to support healthy ageing.

Young at gut: How to modulate the microbiome for healthy ageing?

23 Feb 2026

Should IBD patients avoid prescription NSAIDs?

19 Feb 2026 by

Despite the reported adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in individuals with inflammatory bowel disease (IBD), a study presented at Crohn’s and Colitis Congress 2026 appears to show otherwise.

Should IBD patients avoid prescription NSAIDs?

19 Feb 2026

Ultraprocessed foods are the new cigarettes: study

17 Feb 2026 by

Ultraprocessed foods (UPFs) are associated with several preventable diseases and must be viewed not only through a nutritional lens but also as addictive, industrially engineered substances, which can be likened to cigarettes, suggests a recent study.

Ultraprocessed foods are the new cigarettes: study

17 Feb 2026

Upadacitinib stays effective for 1 year in real-world UC patients

16 Feb 2026 by

Treatment with upadacitinib appears to yield high and durable remission rates in patients with ulcerative colitis (UC), according to 1-year data from a real-world study.

Upadacitinib stays effective for 1 year in real-world UC patients

16 Feb 2026

GLP-1 RAs bring a number of benefits in IBD

15 Feb 2026 by

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with inflammatory bowel disease (IBD) appears to result in favourable clinical outcomes, as shown in two retrospective studies.

GLP-1 RAs bring a number of benefits in IBD

15 Feb 2026

Advanced therapy does not affect time to pregnancy in women with IBD

14 Feb 2026 by

Exposure to advanced therapies, including biologics and small molecules, within 3 months of conception is not associated with an increase in time to pregnancy among women with inflammatory bowel disease (IBD), according to the WIsDoM* trial presented at the Crohn’s and Colitis Congress 2026.

Advanced therapy does not affect time to pregnancy in women with IBD

14 Feb 2026

Mirikizumab improves IBD outcomes during induction, maintenance periods

13 Feb 2026 by

Treatment with mirikizumab results in significant improvements in clinical, endoscopic, and histologic outcomes during induction and maintenance phases in patients with Crohn’s disease (CD) or ulcerative colitis (UC), according to an updated meta-analysis of randomized controlled trials (RCTs).

Mirikizumab improves IBD outcomes during induction, maintenance periods

13 Feb 2026

Vedolizumab vs ustekinumab: Which holds greater advantage for patients with CD?

13 Feb 2026 by

Treatment with either vedolizumab or ustekinumab delivers significant and meaningful benefits to patients with Crohn’s disease (CD), but each has its distinct therapeutic profile with complementary advantages, reports a real-world study presented at CCC 2026.

Vedolizumab vs ustekinumab: Which holds greater advantage for patients with CD?

13 Feb 2026

Peppermint oil, sweets of little benefit in paediatric IBS and functional abdominal pain

13 Feb 2026

Peppermint oil or peppermint sweets appear to do little in terms of relieving pain in children with irritable bowel syndrome (IBS) or functional abdominal pain–not otherwise specified, as shown in a study.

Peppermint oil, sweets of little benefit in paediatric IBS and functional abdominal pain

13 Feb 2026

News & Updates

Showing Gastroenterology articles

Showing

Specialty:

Chronic liver disease ups risk of post-ERCP complications

Chronic liver disease ups risk of post-ERCP complications

Young at gut: How to modulate the microbiome for healthy ageing?

Young at gut: How to modulate the microbiome for healthy ageing?

Should IBD patients avoid prescription NSAIDs?

Should IBD patients avoid prescription NSAIDs?

Ultraprocessed foods are the new cigarettes: study

Ultraprocessed foods are the new cigarettes: study

Upadacitinib stays effective for 1 year in real-world UC patients

Upadacitinib stays effective for 1 year in real-world UC patients

GLP-1 RAs bring a number of benefits in IBD

GLP-1 RAs bring a number of benefits in IBD

Advanced therapy does not affect time to pregnancy in women with IBD

Advanced therapy does not affect time to pregnancy in women with IBD

Mirikizumab improves IBD outcomes during induction, maintenance periods

Mirikizumab improves IBD outcomes during induction, maintenance periods

Vedolizumab vs ustekinumab: Which holds greater advantage for patients with CD?

Vedolizumab vs ustekinumab: Which holds greater advantage for patients with CD?

Peppermint oil, sweets of little benefit in paediatric IBS and functional abdominal pain

Peppermint oil, sweets of little benefit in paediatric IBS and functional abdominal pain